Increased serum FGF23 concentrations were associated with adverse outcomes such as increased mortality in patients undergoing hemodialysis and mortality and cardiovascular events in patients with coronary artery disease (CAD) [5], [6], [7]. The gene discussed is FGF23; the disease is coronary artery disorder.